A conjugate comprising a targeting peptide selected from NGR, isoDGR or RGD combined with a cytokine selected from TNFalpha and TNFbeta for the treatment of mesothelioma
Disclosed are conjugates of cytokines and targeting peptides that is able to bind to a receptor expressed on tumor-associated vessels or to a component of the extracellular matrix associated to the tumor vessels, for treatment of malignant pleural mesothelioma. In particular, the invention provides conjugates comprising the cytokine TNF linked to a peptide containing the NGR motif. The invention further provides pharmaceutical compositions comprising such conjugate and pharmaceutical formulations comprising conjugates dissolved in appropriate buffers.
